Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
-
New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour indications from the combination of eftilagimod alpha (“efti”) and avelumab (BAVENCIO®)
-
Expansion into urothelial cancer builds on core strategy to increase target indications for combination approaches with efti to exploit the full potential of this unique LAG-3 candidate
-
First patient is expected to be enrolled and dosed in H1 of calendar year 2023
SYDNEY, AUSTRALIA – 29 November 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapiesfor cancer and autoimmune disease, is pleased to announce it has signed a Clinical Trial Collaboration and Supply Agreement (“Agreement”) with Merck KGaA, Darmstadt, Germany and Pfizer for a new Phase I clinical study in patients with urothelial cancer, called INSIGHT-005.
For more information, download the attached PDF.
Download this document
